Assessing Patient Eligibility for CAR-T Therapy
Opinion
Video
This segment explores factors influencing patient candidacy for CAR-T therapy, including age, fitness, and relapse specifics, and evaluates key findings from the KarMMa trials to compare ide-cel with other second-line treatment options for multiple myeloma.
Video Player is loading.
Video content above is prompted by the following:
- What factors make Rosie a strong candidate for CAR-T therapy?
- How do considerations like her age, overall fitness, and specifics of her relapse shape your decision?
- Are there other treatment paths you would explore for this patient?
- Let’s examine the data backing the use of ide-cel in this context:
- Which major findings from the KarMMa and KarMMa-3 trials are most relevant to your decision-making?
- How do these outcomes compare with other second-line options available for multiple myeloma?
Recent Videos
Imaging Quality in Prostate Cancer: Impact on Treatment Decision-Making
Exploring Next-Line Options: Therapies Beyond Trastuzumab Deruxtecan in HER2+ MSS Gastric Cancer
Selecting the Optimal PSMA PET Imaging Agent: Clinical Considerations and Data-Driven Decisions
MSS Status and Pembrolizumab: Assessing Benefits and Considering Combinations Beyond Progression in Upper GI Cancer
Second-Line Treatment for Gastric Adenocarcinoma
Advanced Metastatic Gastric Adenocarcinoma: Treatment Approaches
Gastric Adenocarcinoma: Current Treatment Landscape
Adjuvant Nivolumab in Gastric Cancers & CheckMate 8HW
Esophageal/Gastric Adenocarcinoma Standard of Care
BESPOKE: Study Design, Efficacy End Points and Methods
Related Content
